| Canagliflozin | Glimepiride | Std diff |
---|---|---|---|
Number | 113 | 120 | Â |
Clinical background | |||
 Age, yr | 69 ± 9 | 69 ± 9 | 0.058 |
 Male | 88 (78) | 86 (72) | 0.143 |
 Body mass index kg/m2 | 25 ± 3 | 26 ± 4 | 0.094 |
 Systolic BP, mmHg | 125 ± 14 | 125 ± 18 | 0.021 |
 Heart rate, bpm | 75 ± 12 | 72 ± 13 | 0.226 |
Clinical history | |||
 Hypertension | 49 (43) | 53 (44) | 0.016 |
 Dyslipidemia | 46 (41) | 54 (45) | 0.087 |
 Myocardial infarction | 32 (28) | 24 (20) | 0.195 |
 Angina pectoris | 24 (21) | 27 (23) | 0.031 |
 Coronary artery bypass grafting | 12 (11) | 11 (9) | 0.049 |
NYHA | |||
 I | 72 (64) | 76 (63) | 0.008 |
 II | 39 (35) | 40 (33) | 0.025 |
 III | 2 (2) | 3 (3) | 0.051 |
 Unknown | 0 (0) | 1 (1) | 0.130 |
Medications for non-diabetic conditions | |||
 ACEi/ARB | 89 (79) | 88 (73) | 0.127 |
 Beta blocker | 82 (73) | 82 (68) | 0.093 |
 MRA | 42 (37) | 44 (37) | 0.010 |
 Diuretic | 46 (41) | 53 (44) | 0.070 |
 Statin | 87 (77) | 86 (72) | 0.122 |
 Anti-platelet or anti-coagulant | 71 (63) | 66 (55) | 0.160 |
Medication for diabetes | |||
 Insulin | 4 (4) | 3 (3) | 0.061 |
 Metformin | 18 (16) | 26 (22) | 0.147 |
 Alpha-glucosidase inhibitor | 16 (14) | 24 (20) | 0.156 |
 DPP-4 inhibitor | 64 (57) | 63 (53) | 0.083 |
 GLP-1RA | 1 (1) | 1 (1) | 0.006 |
Echocardiography | |||
 TMF-E | 73.6 ± 25.7 | 71.9 ± 30.58 | 0.058 |
 SEP-e′ | 6.27 ± 2.87 | 5.75 ± 2.28 | 0.199 |
 E/e′ | 11.38 ± 5.15 | 11.59 ± 5.29 | 0.040 |
 EF | 56.67 ± 14.47 | 56.64 ± 14.43 | 0.002 |